Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL363411 | 1.00 | ALDH1A1 (0.33) | ALDH1A1LMNATP53KEAP1NFE2L2 | |
| SCHEMBL938323 | 1.00 | ALDH1A1 (0.33) | ALDH1A1LMNATP53KEAP1NFE2L2 | |
| SCHEMBL940213 | 1.00 | ALDH1A1 (0.33) | ALDH1A1LMNATP53KEAP1NFE2L2 | |
| SCHEMBL938325 | 1.00 | ALDH1A1 (0.33) | ALDH1A1LMNATP53KEAP1NFE2L2 | |
| SCHEMBL23525574 | 0.86 | ALDH1A1 (0.37) | ALDH1A1LMNATP53KEAP1NFE2L2 | |
| SCHEMBL941091 | 0.78 | KEAP1 (0.34) | KEAP1NFE2L2 | |
| SCHEMBL17723318 | 0.74 | INPP5A (0.31) | — | |
| SCHEMBL17145783 | 0.74 | INPP5A (0.31) | — | |
| SCHEMBL11053867 | 0.73 | — | — | |
| SCHEMBL3124189 | 0.72 | APLNR (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313377-B1 | TREATMENT OF HELICOBACTER WITH ISOTHIOCYANATES | FAHEY JED W (US) | 2015-01-21 | — | — | EP | claimed |
| US-20120258060-A1 | METHODS FOR PROTECTING THE SKIN FROM RADIATION INSULTS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-10-11 | — | — | US | claimed |
| EP-1890683-B1 | METHODS OF SUPRESSING UV LIGHT-INDUCED SKIN CARCINOGENESIS | UNIV JOHNS HOPKINS (US) | 2011-06-08 | — | — | EP | claimed |
| US-20110014137-A1 | METHODS FOR PROTECTING THE SKIN FROM RADIATION INSULTS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-01-20 | — | — | US | claimed |
| EP-2205237-A1 | METHODS FOR PROTECTING THE SKIN FROM RADIATION INSULTS | Johns Hopkins University (US) | 2010-07-14 | — | — | EP | claimed |
| EP-2163238-A2 | Compound for lightening skin tone comprising sulforaphane or sulforaphene or their derivates | Henkel AG & Co. KGaA (DE) | 2010-03-17 | — | — | EP | claimed |
| US-20090247477-A1 | Methods of suppressing uv light-induced skin carcinogenesis | JOHN HOPKINS SCHOOL OF MEDICINE | 2009-10-01 | — | — | US | claimed |
| WO-2009051739-A1 | METHODS FOR PROTECTING THE SKIN FROM RADIATION INSULTS | JOHNS HOPKINS UNIVERSITY (US) | 2009-04-23 | — | — | WO | claimed |
| EP-1890683-A1 | METHODS OF SUPRESSING UV LIGHT-INDUCED SKIN CARCINOGENESIS | Johns Hopkins University (US) | 2008-02-27 | — | — | EP | claimed |
| WO-2006118941-A1 | METHODS OF SUPRESSING UV LIGHT-INDUCED SKIN CARCINOGENESIS | JOHNS HOPKINS UNIVERSITY (US) | 2006-11-09 | — | — | WO | claimed |
| US-6812248-B2 | Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes | JOHN HOPKINS UNIVERSITY SCHOOL OF MEDICINE | 2004-11-02 | — | — | US | claimed |
| US-20020091087-A1 | Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes | JOHNS HOPKINS UNIVERSITY | 2002-07-11 | — | — | US | claimed |
| WO-2002002190-A2 | PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES BY GLUTATHIONE AND PHASE II DETOXIFICATION ENZYMES | JOHNS HOPKINS SCHOOL OF MEDICINE (US) | 2002-01-10 | — | — | WO | claimed |
| US-20230285500-A1 | Compositions and Methods for Gene Therapy for Corneal Endothelium Disorders | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2023-09-14 | — | — | US | disclosed |
| EP-2782583-B1 | METHODS AND COMPOSITIONS FOR REDUCING ALCOHOL TOXICITY | UNIV JOHNS HOPKINS (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190046530-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS | KONSTANTOPOULOS KONSTANTINOS (US) | 2019-02-14 | — | — | US | disclosed |
| US-20020091087-A1 | Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes | JOHNS HOPKINS UNIVERSITY | 2002-07-11 | — | — | US | disclosed |
| WO-2002015722-A2 | TREATMENT OF HELICOBACTER WITH ISOTHIOCYANATES | FAHEY JED W (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002002190-A2 | PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES BY GLUTATHIONE AND PHASE II DETOXIFICATION ENZYMES | JOHNS HOPKINS SCHOOL OF MEDICINE (US) | 2002-01-10 | — | — | WO | disclosed |
| US-5589504-A | Treatment of newborn jaundice | CORNELL RESEARCH FOUNDATION, INC. (US) | 1996-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190046530-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS | PTGS2, PTGES2, CCAR2 | ALDH1A1 658/4885LMNA 2406/4885TP53 277/4885 |
| US-20120258060-A1 | METHODS FOR PROTECTING THE SKIN FROM RADIATION INSULTS | GSTK1, NFE2L2, NQO1 | ALDH1A1 435/4885LMNA 380/4885TP53 107/4885 |
| US-20110014137-A1 | METHODS FOR PROTECTING THE SKIN FROM RADIATION INSULTS | GSTK1, NFE2L2, NQO1 | ALDH1A1 435/4885LMNA 380/4885TP53 107/4885 |
| US-20230285500-A1 | Compositions and Methods for Gene Therapy for Corneal Endothelium Disorders | KEAP1, NFE2L2, TFAM | ALDH1A1 695/4885LMNA 1544/4885TP53 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.